15th Annual

PANTHEON 2018

PRESENTING DiNA™ AWARDS

Friday, November 30 | San Francisco, CA

California Life Sciences AssociationCalifornia Life Sciences Association

Outstanding Product, Therapeutic

Aimovig

Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related peptide receptor (CGRP-R), which plays an important role in migraine. Aimovig was consistently shown to reduce monthly migraine days, including in more difficult to treat populations, with many patients achieving at least a 50% reduction. The product was approved by the FDA in May 2018.